Fundraising Fox

Nuvaira

Minneapolis, US · Founded 2008 · Delaware corporation · 19 employees on LinkedIn · 3 known investors

Nuvaira develops the dNerva Lung Denervation System, a catheter-based device used in a one-time, outpatient bronchoscopic procedure that disrupts pulmonary nerve input to treat chronic obstructive pulmonary disease (COPD). The treatment targets COPD patients with lung hyperinflation and low emphysema, aiming to preserve lung function, reduce breathlessness, and lower exacerbations.

HardwareHealthtechMedical Devices

Founders & leadership

Nuvaira was founded in 2008 by Martin Mayse and Steve Dimmer.

MM
Martin MayseCo-founder
SD
Steve DimmerCo-founder
DWDennis Wahr
Dennis WahrPresident & CEO
LFLisa Flaherty
Lisa FlahertyChief Strategy Officer
SS
Steve SathreVice President of Finance
SP
Steve PaidoshVice President of Operations
DW
Dennis Wahr M.D.in
DW
Dennis W. WahrNamed on SEC filing

Board

GD
Geoffrey DuykBoard director
DS
Doug SissonBoard director
KN
Kirk NielsenBoard director
DS
Dave StassenBoard director

Investors · 3

Windham Capital PartnersNew York · $1M – $5M
Lightstone VenturesreportedPortola Valleyvia Mike Carusi · board
Qiming Venture PartnersreportedBeijing · $5M – $134Mvia Gary Rieschel · board

Reported raises · per SEC filings

Form D private placements

$154.3M disclosed across 8 rounds · 2014–2026

▶$35.8MraisedMar 2026 · 9 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Edward J. MorganDirector
  • Geoffrey DuykDirector
  • Timothy HerbertDirector
  • Dennis W. WahrExecutive Officer, Director
Offering amount
$63.6M
Amount sold
$35.8M
First sale
Feb 2026
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$979.2KraisedAug 2025 · 8 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Geoffrey DuykDirector
  • Doug SissonDirector
  • Timothy HerbertDirector
  • Dennis W. WahrExecutive Officer, Director
Offering amount
$2.5M
Amount sold
$979.2K
First sale
Aug 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$52.9KraisedMay 2024 · 13 investors · Other Health Care
Officers, directors & promoters on the filing
  • Jonathan RootDirector
  • Timothy HerbertDirector
  • Henry PlainDirector
  • Dennis W. WahrExecutive Officer, Director
  • David Van MeterDirector
  • Jaques EssingerDirector
  • Tom GriffinExecutive Officer
  • Michael A. CarusiDirector
Offering amount
$56.4K
Amount sold
$52.9K
First sale
Apr 2024
Incorporated
Corporation, Delaware
Federal exemptions
04
Full filing on SEC EDGAR ↗
▶$15.1MraisedDec 2023 · 39 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • David Van MeterDirector
  • Timothy HerbertDirector
  • Dennis W. WahrExecutive Officer, Director
  • Tom GriffinExecutive Officer
  • Henry A. PlainDirector
  • Jonathan RootDirector
  • Michael A, CarusiDirector
  • Jacques EssingerDirector
Offering amount
$17.3M
Amount sold
$15.1M
First sale
Nov 2023
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$31.3MraisedJan 2022 · 49 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Jonathan RootDirector
  • Yoh-Chie LuDirector
  • Gary RieschelDirector
  • Dennis W. WahrExecutive Officer, Director
  • Robert O'HollaDirector
  • Tim HerbertDirector
  • Henry PlainDirector
  • Michael A. CarusiDirector
Offering amount
$68.2M
Amount sold
$31.3M
First sale
Jul 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$25MraisedFeb 2019 · 20 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Jonathan RootDirector
  • Christopher ShenDirector
  • Alexander SchmitzDirector
  • Michael A. CarusiDirector
  • Dennis W. WahrExecutive Officer, Director
  • Carolyn NgDirector
  • Henry PlainDirector
Offering amount
$75M
Amount sold
$25M
First sale
Feb 2019
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4MraisedMay 2018 · 9 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Kirk NielsenDirector
  • Dave StassenDirector
  • Mark DeemDirector
  • Dennis W. WahrExecutive Officer, Director
  • Hank PlainDirector
  • Mike CarusiDirector
  • James Lee Tze WeiDirector
Offering amount
$8M
Amount sold
$4M
First sale
Apr 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$42MraisedApr 2014 · 9 investors · Other Health Care
Rule 506(b)
Officers, directors & promoters on the filing
  • Hank PlainDirector
  • Dennis WahrExecutive Officer, Director
  • Lincoln CheeDirector
  • Dave StassenDirector
  • Mark DeemDirector
  • Mike CarusiDirector
  • Kirk NielsenDirector
Offering amount
$42M
Amount sold
$42M
First sale
Apr 2014
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 7

by search overlap
Qnovia6 shared keywordsQnovia develops a portable, pre-filled vibrating mesh nebulizer (RespiRx) that delivers nicotine via ultrasonic nebulization without combustion, paired with a cloud-connected AI platform (Neblit) providing real-time behavioral support for smoking cessation. The company targets patients seeking nicotine replacement therapy in the pulmonary drug delivery and digital health space.
Bioworld4 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Supira Medical4 shared keywordsSupira Medical develops a next-generation percutaneous ventricular assist device (pVAD) to provide temporary mechanical circulatory support for high-risk patients undergoing coronary interventions and those in cardiogenic shock. It is a cardiovascular medical device company formed by the Shifamed innovation hub.
Cqmedical4 shared keywordsCQ Medical develops patient positioning and immobilization products used in radiation therapy, including devices for brachytherapy, SBRT, SRS, and proton treatments. Its offerings serve oncology and radiotherapy clinicians treating cancer and conditions such as osteoarthritis.
Insightra Medical3 shared keywordsInsightra Medical develops intra-aortic balloon pump (IABP) catheters used to temporarily support heart function, including a 7Fr IAB catheter kit compatible with Arrow and Datascope consoles. The products are FDA-cleared medical devices intended for use by medical professionals in cardiac catheterization settings.
IQVIA3 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.
Pacira NASDAQ: PCRX www.pacira.com3 shared keywordsPacira develops and commercializes non-opioid therapies for postsurgical, chronic, and musculoskeletal pain, and is advancing a gene therapy pipeline candidate. It serves patients and healthcare providers seeking alternatives to opioid pain management.

Companies competing with Nuvaira for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Nuvaira has filed a notice of an exempt offering of securities to raise $63,576,279.00 in New Funding. - intelligence360intelligence360.news · Mar 2026Nuvaira raises $15 million in private equity for dNerva lung denervation system - Minneapolis / St. Paul Business Journalbizjournals.com · Dec 2023Minneapolis-Based Nuvaira Raises $79 Million To Fight Chronic Lung Diseasespulse2.com · Feb 2019Nuvaira raises $79m to support COPD device - MassDevicemassdevice.com · Feb 2019Nuvaira raises $79M for lung nerve ablation procedure for COPD and asthma | Fierce Biotechfiercebiotech.com · Feb 2019Nuvaira Announces a $79 Million Financing Round to Pursue Groundbreaking Treatment of COPD - Nuvairanuvaira.com · Feb 2019

Frequently asked questions

What does Nuvaira do?
Nuvaira develops the dNerva Lung Denervation System, a catheter-based device used in a one-time, outpatient bronchoscopic procedure that disrupts pulmonary nerve input to treat chronic obstructive pulmonary disease (COPD). The treatment targets COPD patients with lung hyperinflation and low emphysema, aiming to preserve lung function, reduce breathlessness, and lower exacerbations.
Who founded Nuvaira?
Nuvaira was founded by Martin Mayse, Steve Dimmer in 2008.
Who are Nuvaira's investors?
Nuvaira's investors include Windham Capital Partners, Lightstone Ventures, Qiming Venture Partners.
How much funding has Nuvaira raised?
Nuvaira has disclosed $154.3M raised across 8 rounds.
Where is Nuvaira headquartered?
Nuvaira is headquartered in Minneapolis, US.